The FDA had allowed any manufacturer to sell their antibody tests after validating the results themselves and simply notifying the agency of its plans to sell.
The agency revised that policy May 4 and now requires manufacturers to apply for emergency use authorization within 10 business days after the product hits the market or the test won’t be allowed on the market.
On May 21, the FDA published a list of 29 tests that were either voluntarily withdrawn by the manufacturer or removed by the FDA because the manufacturer hadn’t applied for emergency use authorization.
The FDA said it expects the tests on the removal list will not be marketed or distributed and that it plans to continue to update the removal list.
Read the agency’s full news release here.
More articles on supply chain:
How some states are allocating their share of COVID-19 drug
10 COVID-19 testing updates
HHS gives rural providers $225M for COVID-19 testing
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
